DexCom (DXCM)
(Delayed Data from NSDQ)
$76.55 USD
+0.97 (1.28%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $76.67 +0.12 (0.16%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, DexCom, Inc. has a PEG ratio of 1.91 compared to the Medical - Instruments industry's PEG ratio of 2.49.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DXCM 76.55 +0.97(1.28%)
Will DXCM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DXCM
Investing in the Age of Longevity: Silver Economy Stocks in Focus
Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
DexCom Expands Access and Innovation While Balancing Headwinds
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
Other News for DXCM
DexCom, Inc. (DXCM) Announces Temporary Leadership Changes Amid CEO's Medical Leave
DXCM forms 20 Day Moving Average Resistance on September 15
DexCom (DXCM) Appoints Interim CEO Amid Executive Medical Leave
DexCom CEO takes medical leave
Dexcom CEO Takes Medical Leave, Interim Roles Announced